Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ONO-2808
Study Locations (20)
California
- The Parkinson's Movement and Disorder Institute — Fountain Valley
- University of Southern California — Los Angeles
- David Geffen School of Medicine at UCLA — Los Angeles
- Stanford University School of Medicine — Palo Alto
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton
- Norman Fixel Institute for Neurological Diseases - University of Florida — Gainesville
- Mayo Clinic in Florida — Jacksonville
- University of Miami Miller School of Medicine — Miami
Massachusetts
- Massachusetts General Hospital — Boston
- Brigham and Women's Hospital — Boston
Michigan
- University of Michigan School of Medicine — Ann Arbor
- Quest Research Institute — Farmington Hills
New York
- NYU Langone Health - NYU Dysautonomia Center — New York
- Icahn School of Medicine at Mount Sinai — New York
Colorado
- CenExel Rocky Mountain Clinical Research — Englewood
Connecticut
- Yale School of Medicine - Yale Church Street Research Unit (CRSU) — New Haven
Georgia
- Emory University School of Medicine — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05923866
The ClinicalTrials.gov registry entry for NCT05923866 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 37 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple System Atrophy (MSA) appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05923866 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05923866 about?
NCT05923866 is a clinical study titled "A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy". This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.
What is the current status of trial NCT05923866?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2023-09-22. Estimated completion is 2025-08-31.
What conditions does trial NCT05923866 study?
This clinical trial studies the following conditions: Multiple System Atrophy (MSA). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05923866?
The interventions under investigation include: Placebo (DRUG), ONO-2808 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05923866?
This trial is sponsored by Ono Pharmaceutical Co., which has 37 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05923866 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.